MMS

MMS MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

Early phase oncology trials require critical decisions while data is still emerging, and often misaligned. In a new on d...
04/06/2026

Early phase oncology trials require critical decisions while data is still emerging, and often misaligned. In a new on demand webinar, Making the Right Decisions With Incomplete Evidence in Early Phase Oncology Trials, MMS experts explore how teams interpret evolving safety, PK, biomarker, and early efficacy signals to move programs forward responsibly.

Watch to learn how sponsors distinguish signal from noise, align stakeholders, and make confident in study decisions under uncertainty: Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials

https://hubs.li/Q049G1Tf0

We’re continuing to grow the team and are currently recruiting for a range of exciting roles including:- ICF Writer (...
04/03/2026

We’re continuing to grow the team and are currently recruiting for a range of exciting roles including:

- ICF Writer (UK/US Remote): A great opportunity for someone with strong clinical writing experience to support the development of high‑quality Informed Consent Forms across global studies.
- Business and Finance Analyst (Belfast-based): This role is ideal for candidates with experience in a services‑based environment, including project-based revenue, forecasting, and margin analysis.

If you’re looking to join an award‑winning CRO and work alongside collaborative, passionate experts, apply here: https://hubs.li/Q049q22Q0

We had the privilege of celebrating 20 years of MMS in Bangalore, India, spending time with our India‑based teams, shari...
04/02/2026

We had the privilege of celebrating 20 years of MMS in Bangalore, India, spending time with our India‑based teams, sharing music, food, dance, and cultural traditions.

What began 20 years ago as a vision and a one‑person consultancy has grown into a global, data‑focused CRO. But our purpose has never changed: working together to positively impact lives by supporting the development of life‑changing therapies.

We are incredibly grateful to our colleagues in India for the warmth, hospitality, and passion they bring, not just to this milestone celebration, but to MMS every day.

Click here to learn more about the 20-year impact of MMS: https://hubs.li/Q049p-9P0

It’s been great connecting with colleagues across the biometrics community at PHUSE US Connect 2026, with thoughtful con...
03/25/2026

It’s been great connecting with colleagues across the biometrics community at PHUSE US Connect 2026, with thoughtful conversations around data standards, cross‑functional alignment, and what it takes to deliver submission‑ready outputs in complex development programs.

If you’re attending today, be sure to join Kris Wenzel at 1:30 PM CDT for 'What Pharma Can Learn from Data Science Outside the Industry', exploring how perspectives beyond pharma can inform analytical thinking in clinical development.

Let's continue the conversations at Booth 19.

AI is moving quickly into clinical trial operations, but the real question now centers on governance. Our latest Perspec...
03/24/2026

AI is moving quickly into clinical trial operations, but the real question now centers on governance. Our latest Perspectives article explores how organizations can adopt AI responsibly and still maintain the strict standards expected in regulated clinical environments.

If you are exploring AI in this way, read on and you’ll gain:
- Strong governance frameworks help ensure AI outputs remain transparent, traceable, and aligned with regulatory expectations.
- Cross-functional oversight across clinical, regulatory, and data teams helps organizations apply AI responsibly across trial operations.
- Clear documentation and validation practices strengthen confidence in AI-supported decisions throughout the development lifecycle.

Read the full article now: https://hubs.ly/Q0486ssh0

Day One of PHUSE US 2026 highlighted the value of practical, experience‑led discussion across the biometrics community.V...
03/24/2026

Day One of PHUSE US 2026 highlighted the value of practical, experience‑led discussion across the biometrics community.

Visit MMS at Booth 19 to continue conversations on data standards, cross‑functional alignment, and delivering submission‑ready outputs in complex development programs.

Yesterday, Veera Thota and Ian Lees presented 'Estimand‑Aligned Multiple Imputation Strategies in CNS Trials with Complex Intercurrent Events', examining how thoughtful estimand alignment and missing data strategies can strengthen trial interpretation.

MMS is here to support shared learning across biostatistics, statistical programming, data science, and regulatory submissions. Join Ben Kaspar and Stephine Keeton today at 11:00 AM UTC for 'Building Cross‑Functional Regulatory and Programming Alignment for Successful Submissions'.

PHUSE US Connect starts today, and the MMS team would love to connect onsite! Stop by our booth to meet the team and tal...
03/23/2026

PHUSE US Connect starts today, and the MMS team would love to connect onsite! Stop by our booth to meet the team and talk about how our biometrics and data science experts support complex clinical development programs.

Today, MMS will present a talk titled, “Estimand-Aligned Multiple Imputation Strategies in CNS Trials with Complex Intercurrent Events.” The session explores how thoughtful estimand alignment and missing data strategies can strengthen interpretation in CNS trials where intercurrent events add significant analytical complexity.

Other talks from MMS this week include, “Building Cross-Functional Regulatory and Programming Alignment for Successful Submissions,” and “What Pharma Can Learn from Data Science Outside the Industry.”

If you are attending PHUSE this week, come visit the booth or request a meeting here: https://hubs.li/Q047TzRp0

View the full agenda:
https://hubs.li/Q047TC_T0

Next week, MMS will be speaking on data interpretation in early oncology. The session will address how sponsors can stre...
03/20/2026

Next week, MMS will be speaking on data interpretation in early oncology. The session will address how sponsors can strengthen evidentiary confidence through smarter data strategy, clearer endpoint alignment, and meaningful interim interpretation.

Moderated by Ben Dudley, CCO at MMS, thought leaders on this panel include:
- Andrew Krivoshik, MD, PhD, PE, Chief Medical Officer at PAQ Therapeutics
- Mark Stewart, PhD, Vice President of Science Policy at Friends of Cancer Research
- Aiden Flynn, PhD, Senior Vice President, Strategic Statistical Services at MMS

Strong oncology programs are those that are built on how data is framed, challenged, and communicated to regulators and stakeholders at every stage.

Register now to gain practical insights: https://hubs.li/Q047H9xK0

MMS is growing and we are hiring across several key roles! We are currently looking for experienced Project Managers, Me...
03/19/2026

MMS is growing and we are hiring across several key roles! We are currently looking for experienced Project Managers, Medical Writers, and Statistical Programmers to join our global team supporting complex clinical development programs.

These roles are open globally, and many positions offer remote flexibility, allowing talented professionals to contribute from wherever they work best.

At MMS, you will collaborate with experts in regulatory affairs, biometrics, safety, and clinical data to help sponsors move therapies forward. If you are ready to work on meaningful programs with a team that values collaboration, expertise, and impact, we would love to hear from you.

Explore open opportunities with MMS now: https://hubs.li/Q047mzlF0

03/18/2026

Twenty years ago MMS was founded on a simple belief, that data is the most valuable asset for sponsors, and quality should anchor every decision.

Reflecting on this milestone, our Founder & CEO Dr. Uma Sharma highlights a journey shaped by people, scientific rigor, and trusted partnerships. What began as a focused vision has grown into a global team supporting complex programs, expedited pathways, and high‑stakes submissions worldwide.

As MMS enters its 20th year of service, the commitment to advancing science and supporting better therapies for patients remains stronger than ever.

Clinical data drives every development decision, and that’s why sponsor like this large pharma partner with MMS for clin...
03/17/2026

Clinical data drives every development decision, and that’s why sponsor like this large pharma partner with MMS for clinical data management that delivers speed, visibility, and control across complex studies.

Here is what that looks like in practice.
✅ Smart teams building and managing studies in Rave, Zelta, and Medrio
✅ Deployment of modern technologies including eCOA, eClinRO, ePRO, eDiary, and eConsent
✅ Deep therapeutic expertise across global programs
✅ Proven processes that help studies launch faster and maintain clean, reliable data
✅ Near real-time data visibility through Datacise visual analytics
✅ A single point of contact that simplifies communication and strengthens continuity

Gain clean, reproducible, fit for analysis data by partnering with MMS for Clinical Data Management solutions! See more details at https://hubs.li/Q0473pxh0.

A special day at ACDM Berlin, with Lucy Sutton stepping in to deliver Doreen Van Huyssteen’s session, “Risk‑Based Data M...
03/16/2026

A special day at ACDM Berlin, with Lucy Sutton stepping in to deliver Doreen Van Huyssteen’s session, “Risk‑Based Data Management Success Factors and Associated Risks,” following travel disruption.

Lucy’s willingness to step up at short notice is a great example of exceptional commitment and professionalism. The session explored how RBQM continues to shift data oversight from uniform review models to more targeted, risk‑informed approaches, and what organisations must consider to implement it effectively in practice.

If you’d like to speak with Lucy following the session, please make your way over to Booth #28.

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to MMS:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

MMS is an award-winning, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards.